Author(s)

R. Malberger
A. Shinawi
M. Hamed said
C. Hamza

Why was it done?

We developed a unique ambulatory medical and pharmaceutical service providing treatment for children with autoimmune diseases at Carmel hospital.

What was done?

The ambulatory children’s clinic in Carmel hospital provides several medical services for children including those with autoimmune fever diseases, treated with canakinumab (ILARIS), a monoclonal antibody drug .
The ILARIS is given individually at the clinic during morning hours simultaneously with other treatments. The dosage is calculated individually, the remaining drug goes to waste. The treatment is not supplied by a permanent medical team.
Our initiative aims to establish a specific multidisciplinary service for ILARIS patients which will increase the quality, safety and economic efficiency of the treatment.

How was it done?

1. The current medical service was analyzed including all needs and goals, infrastructures and obstacles.
2. The pharmacy presented a multidisciplinary plane addressing all goals and difficulties suggesting a specific time scheduled for ILARIS treatments exclusively, involving a personal rheumatologist, a trained nursing team and a pharmacist dispensing process.
3. Assessment tools including financial formulas and patients’ questionnaire were established before implementation began.

What has been achieved?

1. The patient receives the services of a personal rheumatologist and a familiar trained nursing staff.
2. From the pharmacy perspective the intervention led to a decrease in prescription, preparation and administration errors as well as an impressive economical decrease in the cost of drug waste, saving more than 400,000$ over 13 months.
3. Questionnaires collected show increase in patients and family satisfaction.
4. Patients do not loose school or work days.
5. Community bonds between families of ILARIS patients were formed.

What next?

creating a unique treatment plan for ILARIS patients, collaboration of nursing, pharmacy and medical teams led to a significant improvement in the quality of care, economic efficiency and an increase in the satisfaction of patients. Our initiative achieved its aim in a short time and can be
applied to a verity of medical services in diverse settings in any clinic or hospital worldwide.

Author(s)

K. Koch, The Pharmacy of the capital region of Denmark, Quality, Herlev, Denmark
R. Højmark, The Pharmacy of the capital region of Denmark, non-sterile production, Herlev, Denmark
L.R. Duckert, The Pharmacy of the capital region of Denmark, non-sterile production, Herlev, Denmark
T. Schnor, The Pharmacy of the capital region of Denmark, production, Herlev, Denmark

Why was it done?

There is an interest in implementing more safe, affordable, and sustainable treatment methods for patients for whom a personalized approach is beneficial. These treatments can be expensive and associated with patient safety and compliance issues. For the pediatric population, many medications are not available in appropriate form or dose and therefore is being manipulated before administration. Extemporaneous oral solutions often have a limited shelf life and bad physical properties or undesirable excipients.
Patients with impaired renal function or need for accurate dose adjustments are also expected to benefit from 3D-printed orally disintegrating tablets (OTDs).

What was done?

The initial steps necessary before implementing 3D-printing for manufacturing personalized ODTs has been identified and completed. The clinical advantages and barriers of the personalized treatment has been discussed interdisciplinary and the new dosage form has been risk evaluated in dialogue with the competent authority. As a result, the best suited technology has been identified.

How was it done?

The European marked has been searched for technologies suitable for extemporaneous personalized production in hospital pharmacies. 3D-printed OTDs was identified as most easily implemented both concerning technology, GMP and patient acceptance.
A dialogue about risks and benefits regarding 3D-ptinted ODTs was initiated with the hospital staff. Risks identified concerned the number of drugs available for 3D-printing, the need for stability testing and resistance from authorities. Benefits like flexibility, just-in-time preparation and patient safety was identified.
A meeting was held with the competent authority, to establish the level of validation, documentation and analysis needed on the final product and starting materials.

What has been achieved?

The necessary steps to get started have been identified and completed. Risks and benefits were assessed, and the decision about implementing 3D-printed ODTs was made. An equipment that is reliable and automated has been sourced.
An API for the initial manufacture was selected, combining clinical relevance and adequate physical properties.
Ink/matrix for the 3D-printer was evaluated and found safe for medicines for children. The matrix is manufactured according to GMP.
A regulatory framework has been agreed upon with the competent authority.

What next?

Validation of the equipment and printing of the first ODTs to be used in the clinic.

Author(s)

ANDREA RODRÍGUEZ ESQUÍROZ, AMAYA ECHEVERRÍA GORRITI, Mª CONCEPCIÓN CELAYA LECEA, MARTA MARÍN MARÍN, LOREA SANZ ÁLVAREZ, PATRICIA GARCÍA GONZÁLEZ, JAVIER GORRICHO MENDIVIL, JAVIER GARJÓN PARRA.

Why was it done?

A prescription alert system was developed in our region for the management of drugs in patients with hepatic cirrhosis.

What was done?

A preliminary study made in our region showed that around one in four prescribed medications in cirrhotic patients are contraindicated or overdosed. Besides, it is estimated that around 38% of cirrhotic patients suffer any adverse effect despite approximately 70% of them are preventable.
In addition, safety problems can emerge due to the lack of data regarding drugs management in patients with cirrhosis.
For these reasons, it was essential to develop a tool that helped clinicians during the prescription process and pharmacists while pharmaceutical validation and medication review.

How was it done?

A computer-generated prescription alert system was developed. This system provides security data and dosing recommendations according to Child-Pugh classification of each patient. Besides, the tool suggests safer alternatives when an unsafe drug is prescribed. These recommendations were extracted from the product information and three databases: UpToDate, RxCirrhosis and Geneesmiddelen bij.
According to last laboratory data available from the electronic medical records such as bilirubin, prothrombin time and albumin, this tool estimates the Child-Pugh score, that must be completed with ascites and encephalopathy grade.
At this time, this tool is only available for clinical pharmacists for validation, and it is expected to be implemented for physicians soon.

What has been achieved?

From May to September 2024, a total of 202 drugs were included, 59 (29.2%) were considered contraindicated in some degree of cirrhosis, so it was recommended not to use. Dose adjustment was proposed in 109 (54.0%) drugs, while in 13.9% the tool recommended a safer alternative drug.
In order to complement this issue, information and training sessions were given about safe management of drugs in cirrhotic patients.

What next?

We are working in order to include safety data about more drugs in this alert system.
We hope this tool can help professionals of other regions and countries.

Author(s)

Christina Anastasiadou – Lead Pharmacist Acute & Emergency Medicine
Karen Dicks – Chief Pharmacy Technician Medicines Management
Radhika Patel – Pharmacy Technician MMS

Why was it done?

Until October 2023, the A&E department in Croydon University Hospital in London lacked a full-time pharmacy service, unlike other London trusts. This has contributed to suboptimal medicine management and a delay in the identification of prescribing errors. This has resulted in longer stays, missed medication doses, and a rise in patient safety incidences. At a hospital level this reduces flow and increases cost due to medication wastage. Ultimately, the aim is to improve the flow of patients within the hospital via timely medicines provision, early clinical pharmacy intervention and early discharge planning.

What was done?

We have obtained funding from the Better Care Fund for a period of 2 years. This funding is aimed at assisting local systems in effectively achieving the integration of health and social care in a manner that promotes person-centred care, sustainability, and improved outcomes for individuals and caregivers. Therefore, we introduced a full-time pharmacy service including one pharmacist and two medicines management technicians (MMTs)—one full-time and one part-time. This initiative was implemented as a 2-year trial period, using key performance indicators (KPIs) to evaluate its effectiveness.

How was it done?

Data has been collected against the below KPIS:
1) Number of drug histories completed on admission, before patient is allocated a ward (by MMT or pharmacist) per calendar month.
2) Number of medicines reconciliations completed (by pharmacist) per calendar month.
3) Number of clinical interventions completed by all members of the pharmacy team.
4) Savings secondary to the use of patient’s own drugs (PODs) brought from home for administration to reduce medicines wastage.
5) Savings due to the return of medicines to inpatient pharmacy for re-use from other patients when appropriate.
6) Time between request of medicines from pharmacy dispensary and medicine being dispensed, checked and released to A&E.
7) Review of stock lists in all areas in A&E.
8) Reduction in omitted doses.
9) Discharge medicines supply and screening from A&E to streamline discharge.
10) Number of patients counselled on their medicines and provided with patient-friendly information on them.
11) Number of referrals to community teams i.e allocated chemist via Discharge Medicines Service, Integrated Care Network (ICN) pharmacists or specialty teams (i.e anticoagulation clinic for newly initiated anticoagulant) to provide continuation of care.
12) Liaising with specialty teams within the hospital to expedite review and treatment in a time efficient and cost-effective way.

What has been achieved?

The current pharmacy team is fully integrated into the A&E service and has contributed significantly towards advancing patient experience, via early pharmacy engagement with patients. During the first 10 months of the project, we have data to show:
1) A 540% increase in drug histories and medicines reconciliation on admission.
2) A 19.525% increase in clinical interventions and early detection of medication errors.
3) We have completed 5 teaching sessions so far, in order to tackle common prescribing and medicines management inaccuracies and embedding solutions into nurses and doctors training.
4) We have contributed towards the reduction in omitted doses by 6%.

Positive contribution towards tackling medicines wastage has been shown too. Our team contributed towards saving £13.110 from April to September 2024 by using PODs for administration in hospital and £10.483 by returning dispensed medications to the inpatient pharmacy for recycling and use for other patients for the same time period.

In addition, the team has completed 66 referrals to the community pharmacy team for follow up on newly started medicines, stopped medicines, adherence concerns and polypharmacy. This is in order to provide continuous care and establish follow-up after discharge from hospital.

All in all, improved safe patients flow in and out of hospital.

What next?

Work towards a business case for a permanent pharmacy service in A&E, to continue further developing the above. Utilise all the skills our MMTs hold, in order to continue working on patient safety, improved flow and cost improvement plans. Introduce a pharmacist-prescriber who will be able to tackle arising problems as soon as possible and provide high quality care in liaison with doctors, nurses and advanced care practitioners.

Author(s)

AGUILAR GUISADO, CAROLINA. PHARMACY SERVICE. EL ESCORIAL UNIVERSITY HOSPITAL
SANCHEZ SUAREZ , SUSANA.PHARMACY SERVICE. EL ESCORIAL UNIVERSITY HOSPITAL
GARCIA GIMENO, M MERCEDES.PHARMACY SERVICE. EL ESCORIAL UNIVERSITY HOSPITAL
OTERINO MOREIRA, IVAN.PHARMACY SERVICE. EL ESCORIAL UNIVERSITY HOSPITAL
FIORANTE EMILSE SILVANA. INTERNAL MEDICINE SERVICE.EL ESCORIAL UNIVERSITY HOSPITAL
BARCIA MARTIN M ISABEL.PHARMACY SERVICE. EL ESCORIAL UNIVERSITY HOSPITAL
SAAVEDRA QUIROS VIRGINIA.PHARMACY SERVICE. EL ESCORIAL UNIVERSITY HOSPITAL

Why was it done?

Current antiretroviral therapies are effective, but adherence can be difficult for some patients, so innovation in parenterally administered antiretroviral treatments can help with adherence, as well as reducing the burden on patients with chronic HIV infection.

What was done?

Aim and Objectives: to implement a pharmaceutical care circuit for dispensing long-acting antiretroviral treatments in adult HIV patients.

How was it done?

Expected Improvements: Optimize antiviral use, enhance patient satisfaction, address adherence and maintain clinical effectiveness.
Circuit Design and Stages: In 2023, Pharmacy and Therapeutics Committee introduced intramuscular antiviral treatment with cabotegravir and rilpivirine, and established use criteria, in collaboration with the Internal Medicine service and Nursing consultation involved in the administration(NP):
1. Adults with undetectable Viral Load (VL) for at least 12 months
2. Treatment duration of 6-12 months
3. No prior resistance to non-nucleoside reverse transcriptase inhibitors or integrase inhibitors
4. Absence of HBV co-infection
5. Not pregnant or planning to conceive
6. Good treatment adherence
Pre-Treatment Circuit:
1. Medical Consultation: Clinical assessment and criteria evaluation.
2. Treatment Request: Physicians submit requests electronically.
3. Pharmacy Evaluation: Assessment of adherence to criteria with communication to the physician. Approved requests result in electronic prescriptions, ensuring correct dispensing.
In-Person Pharmaceutical Care Consultations (FCC):
• The first two visits confirm patient commitment and deliver dosing schedules.
• Medications are dispensed by pharmacy technicians and administered at Nursing practice
• From the third dose, consultations are conducted remotely to monitor adherence and effectiveness.
Nursing practice tasks:
• Confirm patient attendance the day before administration.
• Request medication from the pharmacy for the patient.
• Administer treatment and schedule future appointments based on the established calendar.
Implementation: The program began in November 2023.

What has been achieved?

8 patients were included, achieving 100% compliance from all services involved. Patient satisfaction is high, with undetectable VL maintained for 6-12 months post-treatment change. Mild flu-like symptoms were reported by 2 patients, and 2voluntarily discontinued due to mood concerns. 3 patients are awaiting treatment changes. All patients included underwent face-to-face FCC for the first and second doses, and telematic consultation for successive doses.
Limitations: small sample size.

What next?

This pharmaceutical care circuit can be adapted to various pharmacy services, providing a promising approach for HIV treatment adherence.The sample size needs to be enlarged for further studies.

Author(s)

Yosr Trabelsi, Leila Achour, Ikram Fezaa, Samer Sahbi, Chema Drira

Why was it done?

Never events are serious incidents generally linked to human and/or practical errors, which should never happen. Most of these events are avoidable, and are the subject of specific recommendations for the implementation of appropriate protective measures. According to ANSM (French drug safety agency), potassium chloride (KCl) is among the drugs frequently implicated in Never Events.

What was done?

The aim of this study was to assess the prescription and administration practices of injectable KCL in our hospital.

How was it done?

We carried out a 1-month prospective audit between 1 and 30 September 2024. All the prescriptions of injectable KCL were collected and evaluated by a pharmacist using a data collection form. It was divided into 2 sections: preparation and administration. The reference guideline used for this study was the 2022 ANSM recommendations. The results were analyzed using excel.

What has been achieved?

Fifty-five prescriptions were included. The compliance percentage for prescriptions and administration practices was 31.4% and 30.5 %, respectively. Calculation of total intake was compliant and the total volume of diluent was mentioned in all the prescriptions. In 62% of the prescription, the correct specific units were used and in 38.2 % of cases the correct slow infusion rate was prescribed. Nevertheless, the use of the route was inappropriate since only the IV route was prescribed due to the shortage of oral KCl. For administration, final concentration (≤4g/L) of the KCL infusion was respected in 90.9% of cases and all the preparations were labeled.

What next?

The study revealed several non-conformities, leading to the development of an improvement report. Therefore, we decided to implement a training plan about injectable KCl use to ensure patient safety.

Author(s)

Anette Thomsen, Sarah Mejlvang, Maria Grønkjær

Why was it done?

Automatic multidose Dispensing System (ADS) was implemented in April 2024 in the Hospital Pharmacy Central Denmark Region.
Before the implementation, new software functionalities were developed in the medication module (MEM) of the electronic patient record. The development included creation of new workflows in the wards and in the Pharmacy. A new functionality makes it possible for nurses and pharmaconomists at the hospitals to manually order dose-dispensed medicine (DDM) to patients who are discharged from the wards. The orders are sent from MEM to the ADS on one patient for a given time period. Medication can be ordered hourly until noon.

What was done?

Medicine for 1-5 days of use can be dose-dispensed (DD) for the patients ready for discharge, which gives the following advantages:
-Improved patient safety. The transition from hospital to home now uses a concept regarding DDM that is known in the primary healthcare sector.
-Increased time for the patient to buy new medication at a local pharmacy after discharge.
-Extra time for newly added/removed drugs to be incorporated in future DDM from local pharmacies.
-Less time spent by nurses dispensing medicine for patients who are being discharged.

How was it done?

To support patients in the transition between hospital and home it has been important to make an easy way to order and dispense medication. Following developing tasks has been made:
-Identification of needed functionalities
– Identification of necessary IT-support
– Requirement for ADS
-Developments in MEM Development and implementation of new workflows in the clinic
All points were created in collaboration between doctors, nurses, IT specialists and pharmacy staff.
The development took around one year

What has been achieved?

All clinical wards that receive DDM can now manually order DDM for patients who are on their way home. This is a great help in the clinics.

What next?

Extending the timespan in which it is possible to order DDM to patients who are being discharged is planned.
Qualitative studies in patient safety for patients receiving dose dispensed medicine in the transition between Hospital and home is considered.

Author(s)

Muñoz Cid, CL; Sierra Torres, MI; Sánchez Martín, A; Martín Roldán, A; González Sánchez, B

Why was it done?

A procedure was designed for the registration of drug allergies of patients admitted to the hospital in the electronic prescription program by reviewing the digital medical record.

What was done?

Several issues lead to the need of this development:
-Lack of integration of allergy information from computerized history and electronic prescribing.
-To facilitate the appropriate triggering of alerts, correct allergy terminology, coded properly, and captured in a standard location
-Variability in the recording of this information at the different levels of healthcare (primary care and hospitalized).
-Difficulty in accessing information on drug allergies when prescribing and validating medical treatments.
-To improve Patient safety, there is a high risk of serious adverse events if the patient receives a drug to which he/she is allergic.

How was it done?

-Review of allergy documentation (free text), including a more detailed specification and characterization of the patient´s allergies to coded properly (allergy to medicines or therapeutic groups, contraindications, intolerances).
-Validation and configuration of the alert system stratifying risk by means of different colors of according to the information from the clinical history.
-Development of an algorithm to evaluate how to register each allergy depending on every different situation.
-Elaboration of a procedure to alert management and incorporation into the electronic prescription program.
-Dissemination of the procedure and awareness-raising of the need for proper recording.

What has been achieved?

-Preventing medication errors related to drug allergies and ensuring patient safety.
– Improving access to all allergy information for all healthcare professionals involved in the prescription and validation of medication.
– To have a standardized methodology for recording and coding allergies.
– Integrating medical record information into the electronic prescription system.
– Setting-up an effective alert system to avoid allergy errors in the e-prescribing system.

What next?

We have achieved the implementation in the Pharmacy Service of our hospital, but it has already been taken to the safety committee in order to extend this practice to all the services of our hospital and we are working on the formation of a working group within the Patient Safety Commission. We are considering extending this procedure to primary care in order to address this problem from all healthcare areas.

Author(s)

Elena Blanco Saiz

Why was it done?

It is estimated that over 80% of patients receiving treatment with cetuximab experience acneiform eruptions and/or skin dryness and flaking. Approximately 15% of these cutaneous reactions are severe, including cases of skin necrosis.
These skin lesions may predispose patients to secondary infections, potentially leading to complications such as cellulitis, erysipelas, staphylococcal scalded skin syndrome, necrotizing fasciitis, or sepsis, which can result in death.

What was done?

A kit consisting of an alcohol-free moisturizing cream, an alcohol-free gel, and a sunscreen with a sun protection factor of 100 was provided to patients undergoing treatment with cetuximab for daily skin care.

How was it done?

When the oncology department prescribes cetuximab, the patient is informed that a kit will soon be dispensed.
The pharmacy service reviews daily the patients who will initiate treatment with cetuximab in the day treatment center. If there is a patient starting treatment, nursing staff notify us when they arrive at the center, and the pharmacy dispenses a kit while explaining its contents.
We periodically call the patient to check whether they are continuing to use it correctly, if they have noticed any changes in their skin, what changes they have observed, and whether they have needed to take antibiotics and/or topical corticosteroids.

What has been achieved?

• To date, the kit has been dispensed to 21 patients undergoing treatment with cetuximab.
• It empowers patients by actively involving them in their care.
• It prioritizes the overall well-being of the patient, as it may prevent the onset of dermatological side effects and the use of topical corticosteroids and oral antibiotics.
• The process facilitates the pharmacist’s engagement with the patient in the day treatment center and throughout the treatment, allowing for addressing concerns, answering questions, and providing information about adverse effects.
• It promotes the creation of a multidisciplinary team by involving collaboration between oncology, nursing, and pharmacy.

What next?

We present a practical approach that enhances patient safety during the oncology process.
This practice can be adopted by any center.
It is necessary to continue collecting data to obtain reliable results regarding its impact on improving patient safety.

Author(s)

E. Volpi (1), F. Panizzi (2), B. Mastrelli (2), G. Lo Surdo (1), S. Tonazzini (1), S. Alduini (1), M. Mangione (3), S. Baratta (4), M. Baroni (5), S. Biagini (1)
1. Hospital Pharmacy, Ospedale del Cuore, Fondazione Toscana Gabriele Monasterio
2. Postgraduate School of Hospital Pharmacy, University of Pisa
3. Information systems and information technologies, Fondazione Toscana Gabriele Monasterio
4. Nursing, Technical and Rehabilitation Service, Fondazione Toscana Gabriele Monasterio;
5. Clinical Risk Manager, Fondazione Toscana Gabriele Monasterio

Why was it done?

Medication safety practices are a cornerstone for reducing medication errors and patient harm.
Hospital pharmacist has been recognized as one of main healthcare providers that can support the physicians and the nurses in this item.
The computerized labeling of multidose medicines when they were opened is a good practice for safe medication use which is performed from the Fondazione Toscana G. Monsaterio (Italy) since 2022.

What was done?

The routine control activity of the department’s drug stocks includes the verification of drugs expiration date and the timely removal of drugs before they have expired their validity.
In the case of opened multidose medicines, this operation is more complex as their validity is often reduced.
Our aim was to provide to all healthcare professionals a quick and safe computerized labeling tool, which is constantly updated by the pharmacist based on availability of drugs in the hospital wards.

How was it done?

A multidisciplinary team (pharmacist, nurse and computer scientist) developed a multidose drug labeling system linked to the patient’s medical record which allows the generation of a label every time a prescription for a multidose drug is presented, before patient administration. The team discussed the content of the label and selected the categories of drugs that needs to be included.

What has been achieved?

The categories of drugs included in our program are syrups, oral suspensions, ophthalmological and otological preparations and oral drops. We used a computerized program to fill the information about the validity after opening such as days and storage temperature and indicating the source of the information.
The new system allows to easily check the validity after opening for all multidose drugs, before administration to the patient. This implementation not only guarantees patient safety, but also offers support to all nurses or physicians for any subsequent administration of the same drug and simplifies deadline checking operations of the department’s drug stocks.

What next?

We will continue to keep the labeling program updated by including new drugs available in our hospital. We would like that the information on post-opening shelf life was always included in drug SmPCs and that the good practice of computerized labeling was diffused also in other hospital settings.